专利检索 ap:("CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD." OR "Tianjin Medical University Cancer Institute AND Hospital") AND inv:"LIU, Tao" 第 1 页

1.

发明公开
COMBINED PHARMACEUTICAL COMPOSITION OF C-MET KINASE INHIBITOR AND ANTI-PD-L1 ANTIBODY 审中-公开

公开(公告)号：EP4159238A1

公开(公告)日：2023-04-05

申请号：EP21817364.9

申请日：2021-06-01

申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. , Tianjin Medical University Cancer Institute and Hospital

发明人： ZHANG, Xiquan , WANG, Xunqiang , YU, Ding , LIU, Tao , ZHAN, Xiaole , WU, Naiying

IPC分类号： A61K39/395 , C07D215/22 , C07K16/28 , A61P35/00

摘要： Provided are a combined pharmaceutical composition of an anti-PD-L1 antibody and a c-Met kinase inhibitor, specifically, a combined pharmaceutical composition of an anti-PD-L1 antibody and N-(4-((7-((1-(cyclopentylamino)cyclopropyl)methoxy)-6-methoxyquinolin-4-yl)oxy)-3-fluorophenyl)-N-(4-f luorophenyl)cyclopropane-1,1-dicarboxamide, and the use of the combined pharmaceutical composition in the treatment of cancers, in particular, gastric cancer or liver cancer.